Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong.
Diabetes Res Clin Pract
; 197: 110576, 2023 Mar.
Article
en En
| MEDLINE
| ID: mdl-36780955
ABSTRACT
AIMS:
To evaluate major osteoporotic fracture (MOF) risk among type 2 diabetes patients treated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) across eGFR and albuminuria categories.METHODS:
A population-based cohort of type 2 diabetes patients started on SGLT2i or dipeptidyl peptidase-4 inhibitors (DPP4i) during 2007-2020 was identified from Hong Kong Hospital Authority database. One-to-one propensity score matching was applied to match each SGLT2i user with one DPP4i user. The primary outcomes were 180- and 365-day risks of MOF. Cox proportional hazard regression models were used to estimate hazard ratios (HR).RESULTS:
A total of 28,696 patients (14,348 in each group) were included. Over 180-day follow-up, MOF occurred in 25 (0.17â¯%) SGLT2i users and 24 (0.17â¯%) DPP4i users (incidence of 4.07 and 3.63/1,000 person-years, respectively). At 365â¯days, MOF occurred in 43 (0.30â¯%) SGLT2i users and 44 (0.31â¯%) DPP4i users (incidence of 4.16 and 3.64/1,000 person-years, respectively). Risks of MOF were comparable between two groups at both 180â¯days (HRâ¯=â¯1.13, 95â¯%CI 0.65-1.98, Pâ¯=â¯0.67) and 365â¯days (HRâ¯=â¯1.15, 95â¯%CI 0.75-1.75, Pâ¯=â¯0.52). Subgroup analyses were consistent across age, sex, eGFR, albuminuria, or KDIGO categories.CONCLUSIONS:
Our study did not reveal a statistically significant increase in fracture risk with SGLT2i use compared with DPP4i among type 2 diabetes patients, across eGFR and albuminuria categories.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus Tipo 2
/
Inhibidores de la Dipeptidil-Peptidasa IV
/
Fracturas Osteoporóticas
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
En
Revista:
Diabetes Res Clin Pract
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
China